Clinicopathological features of breast cancers predict the development of leptomeningeal metastases: a case-control study
- 109 Downloads
The incidence of leptomeningeal metastases (LM) in patients with breast cancer (BC) is increasing as a result of increased screening and improved patient survival. However, the median survival time after diagnosis of LM is between 5 weeks (without any treatment) and 5 months (for aggressively treated patients). In an attempt to identify clinicopathological risk factors for LM, we carried out a case-control study of 100 women with BC. Fifty patients with BC and LM were enrolled and an additional 50 patients with BC and no CNS metastases including leptomeningeal spread were selected as controls. Patients who had developed LM were selected between December 2006 and August 2008. The control group was matched for: age at diagnosis, year of diagnosis, and initiation of chemotherapy at BC diagnosis. The ILC type (P = 0.03), ER-negative (P = 0.01) and PR-negative status (P = 0.03), and initial M+ status at BC diagnosis (P = 0.008) tended to be more frequent in LM patients. These characteristics should lead to early appropriate assessments being performed in this targeted population when a neurological complaint appears, in order to detect LM as soon as possible.
KeywordsLeptomeningeal metastases Breast cancer
Conflict of interest
No conflict of interest to declare for any author.
- 4.Chamberlain MC (2009) Leptomeningeal metastasis. Curr Opin Neurol 22(6):665–674Google Scholar
- 7.Wolff AC, Hammond ME, Schwartz JN, American Society of Clinical Oncology/College of American Pathologists et al (2007) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25(1):118–145PubMedCrossRefGoogle Scholar
- 23.Basu S, Chen W, Tchou J et al (2008) Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization. Cancer 112(5):995–1000PubMedCrossRefGoogle Scholar
- 24.Schnitt SJ, Guidi AJ (2004) Pathology of invasive breast cancer. In: Harris JR, Lippman ME, Morrow M, Osborne CK (eds) Disease of the breast cancer, vol 34, 3rd edn. Lippincott, Williams and Wilkins, Philadelphia, pp 541–584Google Scholar